Drug candidates in clinical trials for Alzheimer's disease
SY Hung, WM Fu - Journal of biomedical science, 2017 - Springer
Alzheimer's disease (AD) is a major form of senile dementia, characterized by progressive
memory and neuronal loss combined with cognitive impairment. AD is the most common …
memory and neuronal loss combined with cognitive impairment. AD is the most common …
Glucose transporters in brain: in health and in Alzheimer's disease
L Szablewski - Journal of Alzheimer's Disease, 2016 - journals.sagepub.com
Neurons need a continuous supply of glucose, the major source of energy for mammalian
brain metabolism. The central nervous system is protected by three main physiological cell …
brain metabolism. The central nervous system is protected by three main physiological cell …
Tau‐Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease
The failure of several Phase II/III clinical trials in Alzheimer's disease (AD) with drugs
targeting β‐amyloid accumulation in the brain fuelled an increasing interest in alternative …
targeting β‐amyloid accumulation in the brain fuelled an increasing interest in alternative …
Brain glucose transporters: role in pathogenesis and potential targets for the treatment of Alzheimer's disease
L Szablewski - International Journal of Molecular Sciences, 2021 - mdpi.com
The most common cause of dementia, especially in elderly people, is Alzheimer's disease
(AD), with aging as its main risk factor. AD is a multifactorial neurodegenerative disease …
(AD), with aging as its main risk factor. AD is a multifactorial neurodegenerative disease …
Hippocampal tau pathology is related to neuroanatomical connections: an ageing population-based study
Deposits of abnormally phosphorylated tau protein are found in numerous
neurodegenerative disorders; the 'tauopathies', which include Alzheimer's and Pick's …
neurodegenerative disorders; the 'tauopathies', which include Alzheimer's and Pick's …
Precortical phase of Alzheimer's disease (AD)‐related tau cytoskeletal pathology
K Stratmann, H Heinsen, HW Korf, D Del Turco… - Brain …, 2016 - Wiley Online Library
Alzheimer's disease (AD) represents the most frequent progressive neuropsychiatric
disorder worldwide leading to dementia. We systematically investigated the presence and …
disorder worldwide leading to dementia. We systematically investigated the presence and …
Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027
DM Barten, P Fanara, C Andorfer, N Hoque… - Journal of …, 2012 - Soc Neuroscience
Tau is a microtubule (MT)-stabilizing protein that is altered in Alzheimer's disease (AD) and
other tauopathies. It is hypothesized that the hyperphosphorylated, conformationally altered …
other tauopathies. It is hypothesized that the hyperphosphorylated, conformationally altered …
Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies
The exact mechanisms leading to Alzheimer's disease (AD) are largely unknown, limiting
the identification of effective disease-modifying therapies. The two principal …
the identification of effective disease-modifying therapies. The two principal …
Therapeutic strategies for Alzheimer's disease
DM Barten, CF Albright - Molecular neurobiology, 2008 - Springer
Therapeutic approaches for Alzheimer's disease (AD) are guided by four disease
characteristics: amyloid plaques, neurofibrillar tangles (NFT), neurodegeneration, and …
characteristics: amyloid plaques, neurofibrillar tangles (NFT), neurodegeneration, and …
Contact sport‐related chronic traumatic encephalopathy in the elderly: clinical expression and structural substrates
A. Costanza, K. Weber, S. Gandy, C. Bouras, PR Hof, P. Giannakopoulos and A. Canuto
(2011) Neuropathology and Applied Neurobiology37, 570–584 Contact sport‐related …
(2011) Neuropathology and Applied Neurobiology37, 570–584 Contact sport‐related …